LUC00003I2 - - Google Patents

Info

Publication number
LUC00003I2
LUC00003I2 LU00003C LUC00003C LUC00003I2 LU C00003 I2 LUC00003 I2 LU C00003I2 LU 00003 C LU00003 C LU 00003C LU C00003 C LUC00003 C LU C00003C LU C00003 I2 LUC00003 I2 LU C00003I2
Authority
LU
Luxembourg
Application number
LU00003C
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42781502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00003(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LUC00003I1 publication Critical patent/LUC00003I1/fr
Publication of LUC00003I2 publication Critical patent/LUC00003I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU00003C 2009-03-27 2017-01-03 LUC00003I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16395809P 2009-03-27 2009-03-27
US24731809P 2009-09-30 2009-09-30
PCT/US2010/028653 WO2010111483A1 (fr) 2009-03-27 2010-03-25 Inhibiteurs de la réplication du virus de l'hépatite c

Publications (2)

Publication Number Publication Date
LUC00003I1 LUC00003I1 (fr) 2017-01-19
LUC00003I2 true LUC00003I2 (fr) 2017-04-04

Family

ID=42781502

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00003C LUC00003I2 (fr) 2009-03-27 2017-01-03

Country Status (41)

Country Link
US (4) US8871759B2 (fr)
EP (1) EP2410844B1 (fr)
JP (2) JP5913091B2 (fr)
KR (2) KR20130140219A (fr)
CN (3) CN103880862B (fr)
AU (1) AU2010229833B2 (fr)
BR (1) BRPI1013394B1 (fr)
CA (1) CA2756172C (fr)
CO (1) CO6420390A2 (fr)
CR (1) CR20110506A (fr)
CY (1) CY2017004I1 (fr)
DK (1) DK2410844T3 (fr)
DO (1) DOP2011000298A (fr)
EA (1) EA020898B1 (fr)
EC (1) ECSP11011357A (fr)
ES (1) ES2573088T3 (fr)
FR (1) FR16C1026I2 (fr)
GE (1) GEP20146134B (fr)
HK (1) HK1160359A1 (fr)
HR (1) HRP20160476T1 (fr)
HU (2) HUE027755T2 (fr)
IL (1) IL215094A (fr)
LT (1) LTC2410844I2 (fr)
LU (1) LUC00003I2 (fr)
MA (1) MA33209B1 (fr)
ME (1) ME02418B (fr)
MX (1) MX2011010084A (fr)
MY (1) MY169311A (fr)
NI (1) NI201100172A (fr)
NL (1) NL300858I2 (fr)
NO (1) NO2017006I2 (fr)
NZ (1) NZ595410A (fr)
PE (1) PE20120765A1 (fr)
PL (1) PL2410844T3 (fr)
RS (1) RS54713B1 (fr)
SG (2) SG174929A1 (fr)
SI (1) SI2410844T1 (fr)
TN (1) TN2011000475A1 (fr)
UA (1) UA108351C2 (fr)
WO (1) WO2010111483A1 (fr)
ZA (2) ZA201106807B (fr)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
AU2010229833B2 (en) * 2009-03-27 2014-03-13 Merck Sharp & Dohme Llc Inhibitors of hepatitis C virus replication
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
EP2430015B1 (fr) 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Composés aryles tricycliques condensés utiles pour le traitement de maladies virales
EA027493B1 (ru) 2009-05-13 2017-07-31 Джилид Фармассет Ллс Промежуточные соединения для получения противовирусного соединения
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
US8772505B2 (en) 2009-05-29 2014-07-08 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
NZ591973A (en) 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
KR20120076343A (ko) 2009-09-04 2012-07-09 글락소스미스클라인 엘엘씨 화합물
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
KR20120068947A (ko) * 2009-09-24 2012-06-27 에프. 호프만-라 로슈 아게 Ｃｒａｃ 조절제로서의 인돌 유도체
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011081918A1 (fr) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Inhibiteurs du virus de l'hépatite c
WO2011087740A1 (fr) 2009-12-22 2011-07-21 Schering Corporation Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2013518060A (ja) 2010-01-25 2013-05-20 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2542074A4 (fr) 2010-03-04 2014-05-14 Enanta Pharm Inc Agents pharmaceutiques combinatoires au titre d'inhibiteurs de la réplication du vhc
ES2558554T3 (es) * 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AU2011232331A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
WO2011127350A1 (fr) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2585448A1 (fr) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Composés et méthodes de traitement ou de prévention d'infections à flavovirus
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
CN103459399A (zh) * 2010-09-29 2013-12-18 默沙东公司 用于治疗丙型肝炎病毒感染的四环吲哚衍生物
EP2621931A4 (fr) * 2010-09-29 2014-03-19 Merck Sharp & Dohme Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US20130280214A1 (en) * 2010-09-29 2013-10-24 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040923A1 (fr) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales
US20150158909A1 (en) * 2010-12-15 2015-06-11 Abbevie Inc. Anti-viral compounds
WO2012087976A2 (fr) * 2010-12-21 2012-06-28 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012122716A1 (fr) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés tétracycliques de xanthène et leurs procédés d'utilisation pour le traitement de maladies virales
US8835456B1 (en) 2011-03-18 2014-09-16 Achillion Pharmaceuticals, Inc. NS5A inhibitors useful for treating HCV
EP2696681B1 (fr) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de nucléoside 2'-substitués et procédés d'utilisation de ceux-ci pour le traitement de maladies virales
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5669984B2 (ja) 2011-05-18 2015-02-18 エナンタ ファーマシューティカルズ インコーポレイテッド ５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法
EA201791776A1 (ru) 2011-05-27 2018-04-30 Ачиллион Фармасьютикалз, Инк. Замещенные циклофаны для использования при лечении инфекции вгс
CA2841095A1 (fr) * 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Composes spiro en tant qu'inhibiteurs du virus de l'hepatite c
WO2013016499A1 (fr) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Procédés de préparation de composés du thiophène
WO2013016492A1 (fr) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Composés de thiophène
WO2013030750A1 (fr) 2011-09-01 2013-03-07 Lupin Limited Composés antiviraux
NZ623396A (en) 2011-09-16 2016-07-29 Gilead Pharmasset Llc Methods for treating hcv
KR101326828B1 (ko) 2011-12-07 2013-11-11 현대자동차주식회사 클램핑 장치용 회전모듈
CA2855574A1 (fr) * 2011-12-16 2013-06-20 F. Hoffmann-La Roche Ag Inhibiteurs de ns5a de vhc
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG11201404475TA (en) 2012-02-10 2014-08-28 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2013177241A1 (fr) 2012-05-22 2013-11-28 Trustees Of Dartmouth College Procédé permettant de synthétiser des cycloalcanyl[b]indoles, des cycloalcanyl[b]benzofuranes, des cycloalcanyl[b]benzothiophènes, composés et procédés d'utilisation
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9457039B2 (en) 2012-10-17 2016-10-04 Merck Sharp & Dohme Corp. 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2909172A1 (fr) * 2012-10-17 2015-08-26 F. Hoffmann-La Roche AG Dérivés 6-aminoindole à utiliser en tant qu'antagonistes du canal trp
WO2014059901A1 (fr) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Dérivés nucléosides à substitution 2'-cyano et leurs méthodes d'utilisation pour le traitement de maladies virales
JP2016501200A (ja) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ウイルス性疾患を処置するための２−アルキニル置換ヌクレオシド誘導体
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
WO2014110687A1 (fr) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales
WO2014110688A1 (fr) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Composés tétracycliques à substitution thiophène et leurs procédés d'utilisation pour le traitement des maladies virales
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
WO2014121417A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014121418A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN105189515B (zh) 2013-03-14 2018-07-03 葛兰素史克知识产权第二有限公司 作为溴结构域抑制剂的呋喃并吡啶类
CN104230946B (zh) * 2013-06-06 2017-03-08 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
WO2014205592A1 (fr) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Composés hétérocycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
EP3021845A1 (fr) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Associations comprenant des dérivés de biphényle destinées à être utilisées pour le traitement du virus de l'hépatite c
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
EP3063145A4 (fr) * 2013-10-30 2017-08-23 Merck Sharp & Dohme Corp. Procédé de préparation de composés hétérocycliques tétracycliques
US10167298B2 (en) * 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
WO2015089810A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés tétracycliques hétérocycliques condensés et leurs procédés d'utilisation pour le traitement de maladies virales
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
CN108084172A (zh) * 2014-02-21 2018-05-29 常州寅盛药业有限公司 抗丙肝病毒化合物
ES2689278T3 (es) 2014-05-21 2018-11-13 Bristol-Myers Squibb Company Compuestos de 2-(aril o heteroaril)fenilo (aza)benzofurano para el tratamiento de la hepatitis C
WO2015184644A1 (fr) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 Composés et compositions pharmaceutiques destinés à inhiber le virus de l'hépatite c, et utilisations desdits composés et compositions
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016004899A1 (fr) 2014-07-11 2016-01-14 Merck Sharp & Dohme Corp. Procédé de préparation de composés hétérocycliques tétracycliques
EP3237412A4 (fr) * 2014-12-22 2018-10-17 Merck Sharp & Dohme Corp. Formulations à dispersion solide de composés antiviraux
CN107873023B (zh) 2015-02-02 2021-07-23 福马治疗股份有限公司 作为hdac抑制剂的3-烷基-4-酰氨基-双环[4，5，0]异羟肟酸
WO2016126726A1 (fr) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Acides hydroxamiques bicycliques [4,6,0] en tant qu'inhibiteurs hdac6
US10457690B2 (en) 2015-06-04 2019-10-29 Merck Sharp & Dohme Corp. Process for preparing substituted tetracyclic heterocycle compounds
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017076201A1 (fr) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 Inhibiteurs du vhc, leur procédé de préparation et leur utilisation
US10138219B2 (en) * 2016-02-19 2018-11-27 Pmv Pharmaceuticals Methods and compounds for restoring mutant p53 function
WO2017181383A1 (fr) 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Inhibiteurs du virus de l'hépatite c
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
EP3454862A4 (fr) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
EP3471737A4 (fr) 2016-06-20 2019-12-25 Merck Sharp & Dohme Corp. Composés nucléosides cycliques à substitution phosphate et leurs procédés d'utilisation pour le traitement de maladies virales
WO2017219808A1 (fr) 2016-06-21 2017-12-28 浙江柏拉阿图医药科技有限公司 Inhibiteur du virus de l'hépatite c et application
WO2018032467A1 (fr) * 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Composés tétracycliques substitués par chromane et leurs utilisations dans le traitement de maladies virales
WO2018032468A1 (fr) * 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Composés tétracycliques substitués par hétérocycles et leurs procédés d'utilisation pour le traitement de maladies virales
KR101887969B1 (ko) * 2016-08-30 2018-08-13 한국과학기술연구원 항바이러스 활성을 가지는 카르바졸 화합물
CN109134600B (zh) * 2017-06-19 2021-07-20 杭州国谋生物科技有限公司 作为丙型肝炎抑制剂的烷基及杂环化合物及其在药物中的应用
CN109232612A (zh) * 2017-07-11 2019-01-18 周龙兴 抑制丙肝病毒的化合物、药物组合物及其用途
WO2019057946A1 (fr) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Composés aromatiques multi-cycliques utilisés en tant qu'inhibiteurs du facteur d
WO2020247736A1 (fr) * 2019-06-07 2020-12-10 University Of Massachusetts Inhibiteurs de protéase ns3/4a du virus de l'hépatite c
WO2021061643A1 (fr) 2019-09-23 2021-04-01 Pmv Pharmaceuticals, Inc. Méthodes et composés pour la restauration de la fonction du p53 mutant
US11938124B2 (en) 2020-06-24 2024-03-26 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH478208A (de) * 1965-08-05 1969-09-15 Sandoz Ag Verfahren zur Herstellung von Perinonfarbstoffen
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
AU2001293817A1 (en) * 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
DE602004008633T2 (de) 2003-07-10 2008-01-17 Takeda Cambridge Ltd., CAMBRIDGE Siliziumverbindungen und deren verwendung
DE602005013922D1 (de) * 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2007084413A2 (fr) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Procedes de traitement de l’hepatite c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005298403A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
US7994360B2 (en) * 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
US20110104109A1 (en) 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP1910338B1 (fr) * 2005-07-14 2010-08-25 Irm, Llc Composes et compositions utilises comme mimetiques de la tpo
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
FR2894963A1 (fr) 2005-12-16 2007-06-22 Inst Nat Sante Rech Med Nouveaux composes interagissant avec pea-15
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2185554A1 (fr) 2007-08-09 2010-05-19 Merck Sharp & Dohme Corp. Dérivés de silicium sous la forme d'inhibiteurs d'histone désacétylase
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2010535773A (ja) 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー ウイルス感染を治療するための窒素含有二環式化学物質
ES2391600T3 (es) 2008-02-13 2012-11-28 Bristol-Myers Squibb Company Imidazoli bifenil imidazoles como inhibidores del virus de la hepatitis C
CA2731177C (fr) 2008-07-22 2013-10-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composes de quinoxaline macrocycliques en tant qu'inhibiteurs de protease ns3 du virus de l'hepatite c (hcv)
WO2010041687A1 (fr) * 2008-10-09 2010-04-15 コニカミノルタホールディングス株式会社 Élément de conversion photoélectrique organique, cellule solaire, et réseau de capteurs optiques
WO2010062821A1 (fr) 2008-11-28 2010-06-03 Glaxosmithkline Llc Composés antiviraux, compositions, et procédés d’utilisation
BRPI0922366B8 (pt) * 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
PE20120773A1 (es) 2009-03-27 2012-07-19 Presidio Pharmaceuticals Inc Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c
AU2010229833B2 (en) 2009-03-27 2014-03-13 Merck Sharp & Dohme Llc Inhibitors of hepatitis C virus replication
US8772505B2 (en) 2009-05-29 2014-07-08 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011087740A1 (fr) 2009-12-22 2011-07-21 Schering Corporation Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
ES2558554T3 (es) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
EP2598149A4 (fr) 2010-07-26 2014-09-10 Merck Sharp & Dohme Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
US20130280214A1 (en) 2010-09-29 2013-10-24 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040923A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales
WO2012122716A1 (fr) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés tétracycliques de xanthène et leurs procédés d'utilisation pour le traitement de maladies virales

Also Published As

Publication number Publication date
EP2410844B1 (fr) 2016-03-23
CN102427729A (zh) 2012-04-25
HUE027755T2 (en) 2016-11-28
CO6420390A2 (es) 2012-04-16
KR101387274B1 (ko) 2014-04-25
ZA201106807B (en) 2014-03-26
CY2017004I2 (el) 2017-06-28
US20140371138A1 (en) 2014-12-18
PE20120765A1 (es) 2012-06-29
NZ595410A (en) 2013-12-20
SG174929A1 (en) 2011-11-28
JP2015028055A (ja) 2015-02-12
US20120083483A1 (en) 2012-04-05
NO2017006I2 (no) 2018-11-26
ZA201309504B (en) 2016-07-27
EA201171174A1 (ru) 2012-05-30
US8871759B2 (en) 2014-10-28
IL215094A (en) 2016-07-31
BRPI1013394B1 (pt) 2022-04-19
GEP20146134B (en) 2014-08-11
AU2010229833A1 (en) 2011-10-20
CR20110506A (es) 2011-11-07
KR20110130516A (ko) 2011-12-05
ECSP11011357A (es) 2011-10-31
RS54713B1 (en) 2016-08-31
CY2017004I1 (el) 2017-06-28
CN109651342A (zh) 2019-04-19
WO2010111483A1 (fr) 2010-09-30
SI2410844T1 (sl) 2016-06-30
LTPA2016048I1 (lt) 2017-01-25
EP2410844A1 (fr) 2012-02-01
CN102427729B (zh) 2014-09-03
CA2756172C (fr) 2015-11-24
MY169311A (en) 2019-03-21
JP2012522000A (ja) 2012-09-20
FR16C1026I1 (fr) 2017-02-03
HRP20160476T1 (hr) 2016-06-03
AU2010229833B2 (en) 2014-03-13
JP5932929B2 (ja) 2016-06-08
HUS1700002I1 (hu) 2017-02-28
IL215094A0 (en) 2011-11-30
PL2410844T3 (pl) 2016-08-31
ES2573088T3 (es) 2016-06-06
LUC00003I1 (fr) 2017-01-19
US20150246917A1 (en) 2015-09-03
BRPI1013394A2 (pt) 2016-06-21
NL300858I2 (fr) 2017-04-25
ME02418B (fr) 2016-09-20
DOP2011000298A (es) 2017-07-31
MX2011010084A (es) 2011-10-14
MA33209B1 (fr) 2012-04-02
DK2410844T3 (en) 2016-07-04
TN2011000475A1 (en) 2013-03-27
KR20130140219A (ko) 2013-12-23
JP5913091B2 (ja) 2016-04-27
US20170008906A1 (en) 2017-01-12
UA108351C2 (uk) 2015-04-27
EP2410844A4 (fr) 2012-11-14
FR16C1026I2 (fr) 2018-01-19
CN103880862B (zh) 2018-09-25
US9090661B2 (en) 2015-07-28
EA020898B1 (ru) 2015-02-27
LTC2410844I2 (lt) 2018-11-12
HK1160359A1 (zh) 2012-08-17
NO2017006I1 (no) 2017-01-20
NI201100172A (es) 2012-01-10
SG10201402969QA (en) 2014-09-26
CA2756172A1 (fr) 2010-09-30
CN103880862A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
LUC00003I2 (fr)
BR112012012396A2 (fr)
BR112012008267A2 (fr)
BR112012008195A2 (fr)
BRPI0925311A2 (fr)
BRPI0924307A2 (fr)
BR122021004633A2 (fr)
BR122017024704A2 (fr)
BR112012012487A2 (fr)
BR112012012080A2 (fr)
BR112012009797A2 (fr)
BR112012009446A2 (fr)
BR112012009703A2 (fr)
BR112012010357A2 (fr)
BR112012007656A2 (fr)
BR122019005883A2 (fr)
BR112012014856A2 (fr)
BRPI0924534A2 (fr)
BR112012007654A2 (fr)
BR112012007672A2 (fr)
BR112012005951A2 (fr)
BRPI0924617A2 (fr)
BR122017013721A2 (fr)
BR112012009404A2 (fr)
BR112012007671A2 (fr)